Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Amolyt Pharma S.A.S.

Headquarters: Lyon, France
Website: N/A
Year Founded: 2014
Status: Acquired

BioCentury | Oct 3, 2024
Finance

Kurma investing new fund; Kailera advancing obesity assets with $400M

BioCentury’s latest Venture Report also features news about LoQus23, Aktis, Resolution, Triveni, Flagship and more
BioCentury | Mar 19, 2024
Deals

AZ deepens radiopharma commitment via $2B Fusion takeout

Deal brings more momentum for α-emitters, with Fusion’s lead program contrasting Novartis’ β-emitting Pluvicto
BioCentury | Mar 19, 2024
Deals

Deals Report: AZ buys Amolyt for Phase III asset, Novartis takes out IFM Due

Plus: Merck gains access to Pearl Bio’s synthetic biology platform for up to $1B, Hansoh partners with Biotheus on bispecific ADCs, and more
BioCentury | Mar 14, 2024
Deals

AstraZeneca’s Amolyt takeout among largest ever for a French biotech

Deal for $800M up front adds hypoparathyroidism asset, now in Phase III, to AZ’s Alexion portfolio; shareholders could receive $250M milestone
BioCentury | Nov 14, 2023
Finance

Nov. 13 Quick Takes: Legend finds next CAR partner in Novartis

Plus: EQT, Forbion lead €129M A round for VectorY and updates from ViaNautis Bio, Cartesian, Aclaris, Anthos, Basilea, and Blueberry 
BioCentury | Jan 7, 2023
Deals

Jan. 6 Quick Takes: Pfizer ‘externalizing’ some cancer, rare disease programs

Plus: Column Group leads Synthekine’s $100M series C, and updates from Amolyt, Perceive, bluebird bio, BioNTech and more
BioCentury | Jun 30, 2022
Management Tracks

FDA names Bumpus chief scientist, Marston CMO

Plus Beyer becomes CEO at Kures, and updates from NGM, Apexigen, Achilles and more
BioCentury | Mar 7, 2022
Finance

Aiming to be ‘European anchor’ in expansion rounds, Kurma raises €160M toward growth fund

Seeking to maintain bigger stakes in later rounds, Kurma raises growth fund amid turbulent public markets
BioCentury | Jul 8, 2021
Management Tracks

Chin returns to Arix to rebuild investment team as three more depart; plus ADCendo, Magenta, Junshi, Valneva, Q32 Bio, Outlook, Quotient Catalyst, Kaleido, Amolyt and more

Mark Chin is rejoining Arix Bioscience plc (LSE:ARIX) as managing director with a mandate to rebuild the VC’s investment team. Managing Director Christian Schetter, Principal John Cassidy
Items per page:
1 - 10 of 10